Business Wire

METANOMIC

18.5.2022 09:32:04 CEST | Business Wire | Press release

Share
Metanomic Acquires Intoolab, Developers of the First Bayesian Network Artificial Intelligence Engine

Today, Metanomic (https://www.metanomic.net/ ) announces it has acquired Intoolab A.I (https://www.intoolab.com/ ) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment.

The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine.

A more intelligent approach to video game development and Web3 analytics

Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesian Networks. The solution has already been successfully proven in Healthcare and the technology is now being applied initially to video games and Web3 in a number of core applications -

  • Web 3 Intelligence relating to game and NFT discovery and recommendation for tailored and personalized results to the user or player
  • Game Economy Intelligence providing Economy Balance Prediction, Gamer Categorisation, Gameplay Recommendations, Retention Strategies and NPC Intelligence
  • Ad Categorization delivers analytics around player and consumer classification both on and off-chain for in-game advertising networks to drive more personalized results
  • DeFI Intelligence providing on and off-chain user profiling for DeFi insight into asset purchases and income for new products and services, reputation scoring and more.

“Web3 and metaverse are the next big thing that will affect our everyday lives in so many dimensions and we couldn’t be at a better place and time with our technology, to take the next step and introduce Dynamic Bayesian Networks to this untapped and exciting new market,” said Nikos Tzagkarakis , CEO and Co-founder of IntooLab who joins Metanomic as their incoming Chief AI Officer.

“We knew from the first time we met Theo and the rest of the team, that joining the incredible Metanomic powerhouse is our best bet to be part of an unmatched platform for Web3, game economies and the metaverse.

“The incredible traction we’ve seen across both the traditional games industry, web3, and play-and-earn games for the beta of our economy platform already puts us in a strong position to help developers build more fun and engaging experiences,” Theo Priestley, CEO of Metanomic said.

"With the acquisition of an artificial intelligence platform we can deliver more power to developers through real-time player insight as well as the most advanced game economy solution in the industry.”

With the acquisition also comes the commitment to continue to build the company’s development hub in Greece, supporting the local startup community and tech economy.

Thunderstruck is available for trial and partner integration from today. The Metanomic Engine is a complete, free to use game economy design and run-time solution for game developers across Web3 and traditional games and is currently in a closed beta. To sign up for the waiting list email hello@metanomic.net

About Metanomic

Metanomic is the first and only complete real-time economy as a service platform for developers. Built by professional economists and game designers, the platform utilizes patented algorithms to easily deploy plug and play, interoperable and infinitely scalable game and creator economies ready for web3, metaverse, and play-and-earn games. The platform allows developers to easily and quickly build a fully-scalable and configurable play-and-earn economy that features asset creation engines and fully balanced player markets.

About Intoolab

Founded in 2017, Intoolab has always been technology-first, building the first production ready Dynamic Bayesian Networks intelligence that can be a milestone neurosymbolic step towards A.I. frameworks that understand the human concepts structurally and not just correlationally.

Tzager is the first Bayesian Inference A.I. framework, built for biomedical research, drug discovery, and personalized medicine with the main features being Pathway Simulations, Predictor Research/Models, and Literature Intelligence. Tzager is not just another deep learning algorithm trained to solve very specific problems, but an intelligent system with its own framework.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye